Researchers have announced that Japan’s Ministry of Health has approved a new oral medication called JASCAYD® (nerandomilast) for treating adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). This marks the first new treatment option for IPF in over a decade and introduces a novel approach to managing these serious lung conditions, which involve the buildup of scar tissue that impairs lung function.

For individuals affected by IPF and PPF, this approval is significant as it offers a new way to potentially slow the decline in lung function. The drug has shown to reduce the rate of lung function decline, measured by Forced Vital Capacity (FVC), in clinical trials. In one study, participants taking the higher dose of nerandomilast experienced a 68.8 mL improvement in lung function compared to those on a placebo. This could mean better breathing and quality of life for the estimated 10,000 to 30,000 people living with IPF in Japan, especially since many current treatments have side effects that discourage adherence.

The evidence comes from large Phase III trials, known as FIBRONEER™, which demonstrated that nerandomilast significantly slowed lung function decline compared to placebo. Additionally, a pooled analysis from these trials suggested a 59% reduction in the risk of death for those taking the drug. However, while the results are promising, it’s important to note that the studies did not meet all secondary endpoints, and the most common side effect reported was diarrhea, which was generally mild to moderate.

If you or someone you know is living with IPF or PPF, discussing this new treatment option with a healthcare provider could be beneficial, especially considering its potential to improve lung function and overall health.

Source: globenewswire.com